Fumosorinone

Fumosorinone is a PTP1B and Shp2 inhibitor. Fumosorinone enhances insulin signaling by down-regulating PTP1B expression, increases the phosphorylation levels of IRβ, IRS-2, Akt, GSK3β, and Erk1/2, and has hypoglycemic and insulin resistance-lowering effects. Fumosorinone inhibits the proliferation and cycle arrest of cervical cancer and breast cancer cells. Fumosorinone can be used for research on diabetes and cancer[1][2].

Product Specifications

CAS Number

[1879030-70-2]

UNSPSC

12352005

Target

Akt; ERK; GSK-3; Phosphatase; SHP2

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer; Metabolic Disease

Smiles

O=C1C(C(/C(C)=C/C=C/C=C/C(C)=C/[C@H](C)C[C@H](C)CC)=O)=C(O)C(C2=CC=C(O)C=C2)=CN1O

Molecular Formula

C29H35NO5

Molecular Weight

477.59

References & Citations

[1]Chen C, et al. Cytotoxic activity of Shp2 inhibitor fumosorinone in human cancer cells. Oncol Lett. 2018 Jun;15 (6) :10055-10062.|[2]Liu ZQ, et al. Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice. Toxicol Appl Pharmacol. 2015 May 15;285 (1) :61-70.